Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)
Sponsor: GlaxoSmithKline
Listed as NCT01621802, this PHASE3 trial focuses on Measles-Mumps-Rubella and remains completed. Sponsored by GlaxoSmithKline, it has been updated 9 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Dec 2019 [monthly]
Completed PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Oct 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Altamonte Springs, United States, Anaheim, United States, Ansan, South Korea, Asheboro, United States, Augusta, United States, Baldwin Park, United States, Bardstown, United States, Benton, United States, Birmingham, United States, Burke, United States and 50 more location s